左乙拉西坦浓度与妊娠期癫痫女性癫痫发作频率的关联
这项回顾性队列研究在29例妊娠中每月监测左乙拉西坦(LEV)血清浓度,发现整个妊娠期浓度/剂量比值下降;在孕前12个月内有癫痫发作的患者中,低LEV浓度与癫痫发作频率增加相关(p=0.022),作者据此建议对妊娠期使用LEV者进行治疗药物监测。
要点
- 妊娠期LEV浓度/剂量比值在所有月份均下降,作者推荐对所有妊娠期使用LEV的患者进行治疗药物监测。
- 孕前12个月内有发作的患者中,低LEV浓度与发作频率增加相关(p=0.022),作者建议更密切监测。
- 作者建议非无发作患者LEV浓度维持在孕前浓度的65%以上,无发作患者阈值约为孕前浓度的46%。
核心结论
- 作者推荐对所有妊娠期使用左乙拉西坦的患者进行治疗药物监测,因为LEV浓度在妊娠大多数月份显著下降。
- LEV浓度下降仅与孕前一年内有癫痫发作的患者的发作恶化显著相关,作者建议对非无发作患者更仔细监测。
- 作者建议非无发作患者LEV浓度维持在孕前浓度的65%以上,无发作患者LEV阈值约为孕前浓度的46%。
研究设计与样本
- 回顾性队列研究,纳入使用左乙拉西坦的妊娠患者,共29例妊娠。
- 通过静脉穿刺或干血斑法每月采集血样,至少在受孕前6个月及妊娠每个月份测定抗癫痫发作药物血清浓度。
- 从患者记录中获取妊娠期癫痫发作频率和抗癫痫发作药物剂量。
- 患者分为无发作组和非无发作组,后者包含母亲在孕前超过12个月和不足12个月内有癫痫发作的妊娠。
主要发现
- 在29例妊娠中,整个妊娠所有月份均发现浓度/剂量比值下降。
- 在非无发作组中,低LEV浓度与癫痫发作频率增加相关(p=0.022)。
- 非无发作组的cutoff值为0.466时,灵敏度和特异度之和最高。
关键数值与推荐
- 非无发作组中,低LEV浓度与发作频率增加相关(p=0.022)。
- 非无发作组cutoff值为0.466时,灵敏度和特异度之和最高。
- 作者建议非无发作患者LEV浓度维持在孕前浓度的65%以上。
- 作者建议无发作患者LEV阈值约为孕前浓度的46%。
临床怎么用
- 作者推荐对所有妊娠期使用LEV的患者进行治疗药物监测。
- 作者建议对非无发作患者更仔细监测,因其发作频率增加风险更高。
- 作者建议非无发作患者LEV浓度维持在孕前浓度的65%以上,无发作患者阈值约为孕前浓度的46%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Pharmacologic treatment of epilepsy in pregnant women is balancing between risks for the mother and fetus. Levetiracetam (LEV) is considered to be safe during pregnancy because of its low teratogenic potential and lack of drug-drug interaction with other antiseizure medications (ASMs). Recent studies have shown decline of ASM concentrations during pregnancy because of physiologically based pharmacokinetic changes. In this study, we established this decrease in LEV concentration during pregnancy. In addition, we aimed at investigating the effect of the low LEV levels during pregnancy and developing a target value for the level during pregnancy. METHODS: Pregnant patients using levetiracetam were studied in this retrospective cohort study. Blood samples were monthly collected through venous puncture or the dried blood spot method. ASM serum concentrations were determined at least 6 months before conception and for each month of pregnancy. Seizure frequency and ASM dosages during pregnancy were obtained from patient records. Patients were divided into 2 groups: a seizure-free group and a non-seizure-free group, which contained pregnancies in which the mother had experienced an epileptic seizure more than 12 months and less than 12 months before pregnancy, respectively. RESULTS: We found decreased concentration/dose ratios in 29 pregnancies throughout all months of pregnancy. In the non-seizure-free group, it was found that low LEV concentrations were associated with seizure increase frequency (p = 0.022). For this group, the cutoff value with the highest sum of sensitivity and specificity was 0.466. DISCUSSION: All in all, we recommend therapeutic drug monitoring for all pregnant patients on LEV as the concentrations of LEV significantly decrease throughout most months of pregnancy. However, this decrease in LEV concentration was only significantly correlated with seizure deterioration in patients who had a seizure in the year preceding the pregnancy. Therefore, we suggest more careful monitoring of non-seizure-free patients as they are at higher risk for experiencing an increase of seizure frequency. For this group, we advise physicians to keep LEV concentration above 65% of the preconceptional concentration. For seizure-free patients, we recommend an LEV threshold value of approximately 46% of the preconceptional concentration.
引用
- Schelhaas M, Wegner I, Edens M, et al. Association of Levetiracetam Concentration With Seizure Frequency in Pregnant Women With Epilepsy. Neurology. 2022. PMID: 36257713. doi:10.1212/WNL.0000000000201348
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。